Outcomes of first-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
Chun Loo Gan(University of Calgary), Daniel Yick Chin Heng(University of Calgary), Ziad Bakouny(Dana-Farber Cancer Institute), J. Connor Wells(Queen's University), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Ravindran Kanesvaran(University of Ioannina), Sumanta K. Pal(City of Hope), Toni K. Choueiri(Harvard University), Bernadett Szabados(Queen Mary University of London), Rana R. McKay(University of California San Diego), Frede Donskov(Aarhus University Hospital), Jae‐Lyun Lee(Ulsan College), Ian D. Davis(Austin Health), Lori Wood(Dalhousie University), Christian Kollmannsberger(BC Cancer Agency), Andrew Schmidt(Dana-Farber Cancer Institute), Guillermo de Velasco(Dana-Farber Cancer Institute), Shaan Dudani(William Osler Health System), Francis Parnis(Centre for Cancer Biology), Shirley Wong(Western Hospital)
Cited by 11
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k